RapidQ S-IgG Card™: The rapid test for the quantification of level of antibodies against the SARS-CoV-2, the virus that causes COVID-19

This product is not been approved by the FDA. It has been developed under NIH funding. It is currently not available for use other that research purposes.

Why is the quantification of Antibody level Critical? 

As in other viral infections, the immune system responds to COVID-19 by developing antibodies against the SARS-CoV-2 virus. The antibody titer (concentration) can reveal present and past infections and immunocompetence. Titer tests have been a valuable tool to determine individual immunity for other viral infections, such as rubella, measles, Hepatitis B, and Varicella. 

Currently marketed lateral flow serological tests are qualitative assays and provide only a yes/no answer, hence they are unable to provide a full picture of the antibody titer, its trend over time, the course of infection, and possible level of immunity. 

On the contrary, the RapidQ S-IgG Card combines ease of use, a low cost, and mobile connectivity with reliable quantitative antibody titer capabilities to aid in the identification of the disease progression, the degree of immunocompetence, and the spread of herd immunity.

The statements in the page have not been reviewed by the FDA.